October 23, 2026- The U.S. Food and Drug Administration announced the launch of the Neuroscience Advancement and Innovation Nexus (NAIN), a new agency program aimed at delivering breakthrough treatments. NAIN is designed to advance the science, tools, and regulatory approaches needed to support the development of medical products for conditions affecting the brain and nervous system.
NAIN’s inaugural initiative, the Alzheimer’s Prevention Accelerator, will focus on advancing medical products that help delay or prevent Alzheimer’s disease. Both efforts support the National Alzheimer’s Project Act (NAPA), the federal government’s comprehensive roadmap for coordinated action on Alzheimer’s and related dementias.